Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically confirmed local advanced unresectable/metastatic adenocarcinoma of biliary tract~* measurable disease~* available tumor tissue for investigational immunohistochemical evaluations~* ECOG PS 0-2~* No prior chemotherapy, biologic therapy or radiation therapy~* Age Eighteen and older~* Lab values per protocol~Exclusion Criteria:~* Life expectancy less than three months~* Concurrent use of chemotherapy not indicated in the study protocol or any other investigational agents and patients who have received investigational drugs less than four weeks prior to enrollment~* Prior therapy, which affects or targets the EGF pathway~* Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer~* Recovery from major surgery within three weeks of the start of study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: EXPERIMENTAL): Gemcitabine (Days 1, 8), irinotecan (days 1, 8) and panitumumab (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.

Based on this trial design, predict the completion outcome and termination type (if applicable).